# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
480 out of 500 S&P 500 companies are trading below analysts' price targets, indicating potential profit opportunities. ...
The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more bro...
Last will remain part of Bio-Rad's executive leadership team to ensure a smooth transition while the company conducts a sea...
Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price targe...
Wall Street takes pause after stronger-than-expected producer inflation report, potentially delaying Fed rate cuts and impactin...
RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target f...
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.